Macular Degeneration

"Macular Degeneration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.

Descriptor ID	D008268
MeSH Number(s)	C11.768.585.439
Concept/Terms	Macular Degeneration Macular Degeneration Degeneration, Macular Degenerations, Macular Macular Degenerations Age-Related Maculopathies Age Related Maculopathies Macular Degeneration, Age-Related Macular Dystrophy Dystrophies, Macular Dystrophy, Macular Macular Dystrophies Maculopathies, Age-Related Maculopathies, Age Related Maculopathy, Age-Related Maculopathy, Age Related Age-Related Macular Degeneration Age Related Macular Degeneration Age-Related Macular Degenerations Degeneration, Age-Related Macular Degenerations, Age-Related Macular Macular Degenerations, Age-Related Age-Related Maculopathy Age Related Maculopathy

Below are MeSH descriptors whose meaning is more general than "Macular Degeneration".

Diseases [C]
Eye Diseases [C11]
Retinal Diseases [C11.768]
Retinal Degeneration [C11.768.585]
Macular Degeneration [C11.768.585.439]

Below are MeSH descriptors whose meaning is related to "Macular Degeneration".

Below are MeSH descriptors whose meaning is more specific than "Macular Degeneration".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Macular Degeneration" by people in this website by year, and whether "Macular Degeneration" was a major or minor topic of these publications.

Bar chart showing 154 publications over 23 distinct years, with a maximum of 14 publications in 2006 and 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	8	0	8
2003	2	1	3
2004	7	1	8
2005	8	1	9
2006	10	4	14
2007	14	0	14
2008	7	1	8
2009	8	2	10
2010	6	3	9
2011	4	2	6
2012	2	1	3
2013	3	0	3
2014	6	1	7
2015	7	1	8
2016	3	0	3
2017	12	1	13
2018	2	0	2
2019	1	2	3
2020	5	0	5
2021	9	0	9
2022	7	0	7
2023	1	0	1

Below are the most recent publications written about "Macular Degeneration" by people in Profiles.

Fujimoto S, Kokame GT, Ryan EH, Johnson MW, Hirakata A, Shirriff A, Ishikawa H, Adams OE, Bommakanti N. Macular Retinoschisis from Optic Disc without a Visible Optic Pit or Advanced Glaucomatous Cupping (No Optic Pit Retinoschisis [NOPIR]). Ophthalmol Retina. 2023 09; 7(9):811-818.

View in: PubMed
Wang R, McClard CK, Laswell S, Mahmoudzadeh R, Salabati M, Ammar M, Vannavong J, Aziz AA, Ewald A, Calvanese AV, Lehman EB, Fried S, Windham V, Strutt A, Saroj N, Khanani AM, Eichenbaum DA, Regillo C, Wykoff CC. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022 Dec; 7(1).

View in: PubMed
Grant MB, Bernstein PS, Boesze-Battaglia K, Chew E, Curcio CA, Kenney MC, Klaver C, Philp NJ, Rowan S, Sparrow J, Spaide RF, Taylor A. Inside out: Relations between the microbiome, nutrition, and eye health. Exp Eye Res. 2022 11; 224:109216.

View in: PubMed
Shah SM, Boopathiraj N, Starr MR, Dalvin LA, AbouChehade J, Damento G, Garcia MD, Hodge DO, Bakri SJ, Sit AJ, Iezzi R. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2022 11; 243:98-108.

View in: PubMed
Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, Holz FG. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials. Ophthalmologica. 2022; 245(5):403-412.

View in: PubMed
Light JG, Pyfer MS, Salabati M, Mahmoudzadeh R, Wakabayashi T, Ho AC. Stellate nonhereditary idiopathic foveomacular retinoschisis and an approach to the differential diagnosis of macular star. Curr Opin Ophthalmol. 2022 May 01; 33(3):157-166.

View in: PubMed
Salabati M, Obeid A, Mahmoudzadeh R, Gupta O, Chiang A, Spirn M, Klufas MA, Hsu J. Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022 Aug; 260(8):2509-2516.

View in: PubMed
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 02 19; 399(10326):729-740.

View in: PubMed
Starr MR, Fairbanks AM, Geraets R, Chen J, Pulido JS. PERSISTENT PLACOID MACULOPATHY-LIKE FINDINGS IN PATIENTS WITH GIANT CELL ARTERITIS. Retin Cases Brief Rep. 2021 Nov 01; 15(6):682-687.

View in: PubMed
Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer "cell therapy" clinics. Stem Cell Res Ther. 2021 10 11; 12(1):538.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement